Tag Archives: Exosome Diagnostics

Researchers from Exosome Diagnostics show that tumor- derived RNA was not detected in thrombocytes in samples where the tumor RNA was readily detected in exosomes. This finding holds significant implications for developers of liquid biopsies...

Bio-Techne have researchers published a validation study demonstrating that the proprietary exosome-based liquid biopsy tests from Bio-Techne’s Exosome Diagnostics brand may be used to assess the...

Bio-Techne Corporation announced today that it has reached agreement to acquire Exosome Diagnostics, Inc. for $250 million in cash plus contingent consideration of up to $325 million due upon the achievement of certain future milestones. The transaction is expected to ...

This groundbreaking observation is presented as Late Breaking Research at the AACR Annual Meeting in Chicago on Tuesday by Dr Sudipto Chakrabortty.

CareFirst BlueCross BlueShield (CareFirst), today announced that it has reached a positive coverage decision for the ExoDx® Prostate(IntelliScore) or EPI test – meaning that the test will be covered for CareFirst members beginning in 2018. This coverage decision is based ...

Exosome Diagnostics, Inc., and MD Anderson Cancer Center had a unique study published in Clinical Cancer Research, a peer reviewed publication of the American Association of Clinical Cancer Research. The analysis directly compared Exosome Diagnostics’ ExoLution® Plus platform with two ...

Exosome Diagnostics, a leader in the liquid biopsy market, today announced the launch of the MedOncAlyzer 170, the first liquid biopsy pan-cancer panel that simultaneously interrogates exosomal RNA (exoRNA) and circulating tumor DNA (ctDNA) in a single assay. The MedOncAlyzer ...

Exosome Diagnostics Inc., a leader in the liquid biopsy market, today announced the close of its $30 million Series C financing, led by insiders, Tiger Partners and Forbion Capital Partners. Blue Ridge Capital, NGN Capital, Arcus Ventures, b-to-v Partners, CD ...

NEW YORK (360Dx) – A multiplexed nanoplasmonic assay designed specifically to fit into clinical workflows is taking aim at high-throughput detection of pancreatic ductal adenocarcinoma (PDAC), an aggressive and often inoperable form of pancreatic cancer. Developed by researchers at Harvard ...

This position will be responsible to lead the research and development efforts to develop commercially viable methods to utilize Exosome technology for cancer, neurodegenerative and other diseases. The candidate must have strong technical skills in the areas of qPCR and ...